ReviewFrontiers in oncology2019
Chimeric Antigen Receptors for T-Cell Malignancies.
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Advances and Perspectives in the Treatment of T-PLL.Current hematologic malignancy reports · 2020Pooled it
- Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia.Nature immunology · 2025Article
- CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.Journal of hematology & oncology · 2025Article
- K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies.Molecular therapy. Oncology · 2025Article
- DNA Aptamer-Polymer Conjugates for Selective Targeting of Integrin α4β1ACS applied materials & interfaces · 2025Article
- Case report of non-gene editing CD7 CAR T cell therapy in CD7Frontiers in immunology · 2025Article
- Exploring the Biological Activity of a Humanized Anti-CD99 ScFv and Antibody for Targeting T Cell Malignancies.Biomolecules · 2024Article
- Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity.Cell reports. Medicine · 2024Article
- INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.Transplantation and cellular therapy · 2024Review
- Transcriptome Analysis Reveals the Induction of Apoptosis-Related Genes by a Monoclonal Antibody against a New Epitope of CD99 on T-Acute Lymphoblastic Leukemia.Antibodies (Basel, Switzerland) · 2024Article
- CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia.Exploration of targeted anti-tumor therapy · 2024Review
- Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9.Frontiers in immunology · 2024Review
- Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas.Hematology/oncology clinics of North America · 2023Review
- TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones.Blood advances · 2023Article
- The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives.Experimental hematology & oncology · 2023Review
- Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Adoptive Cell Therapy for T-Cell Malignancies.Cancers · 2022Review
- Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.Journal for immunotherapy of cancer · 2022Article
- [Hepatocellular carcinoma immune microenvironment].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Review
- T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed on non-malignant T cells. Transducing T cells with CARs targeted to these shared antigens can therefore promote over-activation or fratricide of CAR T cells, reducing their therapeutic potency. If fratricide is resolved, clinical CAR T cell activity may eliminate normal T-cell subsets and cause temporary immunosuppression. In this review, we summarize the preclinical development of CAR-based therapies for T-cell malignancies and discuss strategies to minimize toxicities associated with on-target fratricide and off-tumor activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.